News Novo's Saxenda label to include cardio data Label will reflect heart benefit seen in LEADER trial.
News Novartis' canakinumab cuts risk for heart attack survivors Novartis to discuss canakinumab results with regulators.
News J&J diabetes drug hit by amputation risk Invokana produces modest CV benefit, but doubles risk of amputation
News Pfizer drug gets fast review in rare heart condition FDA grants faster and development and review process.
Views & Analysis ADA preview: cardio data in diabetes, drug costs and healthc... Invokana data could suggest cardio benefit for SGLT2 class.
News Novo hopes hypoglycaemia data will boost Tresiba Lower severe hypo risk compared with Lantus - but no cardiac benefit.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
